Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, August 19 at 2:00 PM EDT

Register Free →

TRIPLE F FARMS, LLC

UEI: JDPXL5KDRHA8CAGE: 91AY0

TRIPLE F FARMS, LLC is a federal contractor, registered under UEI JDPXL5KDRHA8 and CAGE code 91AY0. It has been awarded $1,156,623 across 22 federal contracts. Primary work spans All Other Animal Production. Top awarding agencies include Department Of Health And Human Services and Department Of Agriculture.

Contact Information

Registration and classification details

Registration

UEI Code

JDPXL5KDRHA8

CAGE Code

91AY0

Entity Structure

Partnership or Limited Liability Partnership

Established

N/A

Business Classifications

2XLJ

NAICS Codes

112990All Other Animal Production(Primary)

Federal Contracting Overview

Award totals, agency breakdown, NAICS distribution, and geographic footprint.

AI Capability Profile

TRIPLE F FARMS, LLC specializes in the breeding and supply of specialized laboratory animals for biomedical research, with a singular focus on ferrets under stringent pathogen-free and antigen-free conditions. Their core capabilities center on maintaining controlled breeding environments that meet r...

TRIPLE F FARMS, LLC specializes in the breeding and supply of specialized laboratory animals for biomedical research, with a singular focus on ferrets under stringent pathogen-free and antigen-free conditions. Their core capabilities center on maintaining controlled breeding environments that meet rigorous biocontainment standards, ensuring animals are free from influenza and other infectious agents critical to preclinical virology and respiratory disease studies. The contractor demonstrates deep technical expertise in animal health monitoring, pathogen screening protocols, and genetic lineage control, enabling consistent delivery of high-integrity research models. Their ability to consistently produce antigen-free and pathogen-free ferrets positions them as a niche provider for agencies requiring reproducible, immunologically clean subjects for vaccine development, antiviral testing, and respiratory pathogen transmission studies. The contractor maintains a consistent and exclusive relationship with the Department of Health and Human Services, supplying ferrets for research programs likely tied to the National Institutes of Health and the Centers for Disease Control and Prevention. Their contract history reflects sustained demand for specialized animal models in public health research, particularly in areas requiring controlled infection models and immune response analysis. Their primary NAICS code, 112990 — All Other Animal Production — reflects a highly specialized vertical in laboratory animal husbandry, distinct from commercial livestock or pet breeding. This places them in the preclinical research supply chain, serving the biomedical and pharmaceutical sectors with precision-bred animal models. TRIPLE F FARMS, LLC is a small, privately held entity based in Gillett, Pennsylvania, with no federal certifications on record. Their geographic presence is localized, but their market positioning is nationally significant within the specialized research animal supply sector, serving critical federal health research missions through highly targeted biological production capabilities.

Key Performance Metrics

Awards Count

0

All time

Active

0

Currently performing

Completed

0

Past period of performance

Total Awards

All time

Contracts

Prime · all time

Subcontracts

Sub · all time

Grants

Prime · all time

Subgrants

Sub · all time

Award Analytics & Distribution

Awards by Agency
Department Of Health And Human Services$1.1M97.6%
Department Of Agriculture$27.9K2.4%
Awards by NAICS
112990 - All Other Animal Production$1.2M100%
Awards by Agency Over Time
Export
Awards by Place of Performance

Open opportunities in TRIPLE F FARMS, LLC's top NAICS codes and agencies

NAICS: 513210
New
Federal
Notice of Sole Source: GastroPlus PBPK and PBBM modeling platform subscription
Solicitation # 7571TE26Q00153
The U.S. Food and Drug Administration, through the Department of Health and Human Services, intends to sole-source a firm fixed-price contract to Simulations Plus Inc. for twenty GastroPlus and five DDDPlus software licenses, used for physiologically based pharmacokinetic and physiologically based biopharmaceutics modeling in support of generic drug research. The contract spans a base year from September 1, 2026, to August 31, 2027, with up to three one-year option periods extending through August 31, 2030. Performance will occur at the FDA’s White Oak campus in Silver Spring, Maryland. The acquisition is conducted under RFO 12, allowing for non-competitive procurement of commercial products, and no set-aside applies. Responses are due by August 14, 2026, and any interested party may submit a capability statement to demonstrate their ability to supply the exact software licenses as the original equipment manufacturer or authorized reseller, which the government will review solely to determine whether competitive procurement is warranted. The contract requires the vendor to provide standard individual licenses, with no auto-renewals permitted unless explicitly authorized. Acceptance of deliverables will be conducted by the Contracting Officer’s Representative within 30 working days of delivery, verifying software functionality, compatibility with FDA systems, and compliance with technical requirements. Invoicing must be submitted electronically through the Treasury’s Invoice Processing Platform, and all invoices must include detailed supporting documentation for labor, materials, and costs. The government retains the right to reject nonconforming deliveries and will not pay for services that fail to meet agreed standards. Clauses from the FAR and HHSAR govern payment, representation, whistleblower rights, anti-lobbying, accessibility, and dispute resolution, with federal regulations taking precedence over any vendor terms. The Contracting Officer and Contract Specialist are the primary points of contact, and all vendors must be actively registered in SAM at the time of submission.
Department Of Health And Human Services

POSTED

1 day ago

DEADLINE

in 9 days
View Details
NAICS: 112990
New
SLED
RFQ-2026-IDR6-001, Live Pheasants
Solicitation # 0000039905
The State of California is soliciting bids for the supply of live, healthy, male ring-necked pheasants to support hunt events scheduled between November 2026 and January 2027. The solicitation, identified as RFQ-2026-IDR6-001 and tender number 0000039905, requires vendors to provide only male pheasants that meet specific health and fitness standards to ensure suitability for release during managed hunting opportunities. The closing date for submissions is August 17, 2026, at 2:00 PM Pacific Time, with all responses due by this deadline. Interested vendors must direct all inquiries to Tanya Bennett at tanya.bennett@wildlife.ca.gov and should be aware that registration on the State of California’s official procurement portal may be necessary to participate in the bidding process. The pheasants are to be delivered for performance at West Sacramento, California, with a postal code of 95605. The procurement is managed by the California Department of Fish and Wildlife, with Tanya Bennett serving as the primary point of contact for the request. While the solicitation is listed under the State of California’s agency, bidders are advised to verify all requirements and registration procedures directly through the official state channels, as Biddingo.com provides this information for reference only and is not responsible for third-party website content or accuracy. Potential suppliers should ensure compliance with all state-imposed conditions regarding animal health, transportation, and delivery timelines, as failure to meet these specifications may result in bid disqualification. The contract does not specify a set-aside classification or NAICS code, and vendors are encouraged to consult the originating source for any additional terms, conditions, or technical details not outlined here.
State of California

POSTED

2 days ago

DEADLINE

in 12 days
View Details
NAICS: 541715
New
Federal
Antioxidant Therapy for Smith-Lemli-Opitz Syndrone
Solicitation # NICHD-08610
The contract pertains to the development and implementation of antioxidant therapy for Smith-Lemli-Opitz Syndrome, a rare genetic disorder characterized by multiple congenital anomalies and metabolic dysfunction. The solicitation, issued under NICHD-08610 by the Department of Health and Human Services through its National Institutes of Health, invites proposals aimed at advancing targeted antioxidant interventions to mitigate the pathological effects of the condition. The opportunity was posted on August 3, 2026, with responses due by August 18, 2026, at 2:00 PM Eastern Time. The work is expected to be performed in Bethesda, Maryland, consistent with the research infrastructure of the NIH campus. All proposals must be submitted through the SAM.gov portal and should address scientific rigor, feasibility, and potential clinical impact. The primary point of contact for inquiries is Niamh Cawley, with Chung Huang as the secondary contact, both reachable via NIH email addresses. The contracting activity falls under the Department of Health and Human Services with no set-aside provisions specified, and no NAICS code is assigned, indicating flexibility in contractor categorization. Interested parties should ensure adherence to deadlines and submission requirements outlined on the official UI link linked in the posting.
Department Of Health And Human Services

POSTED

3 days ago

DEADLINE

in 12 days
View Details
NAICS: 562111
New
Federal
Notice of Intent / Sole Source Solid Waste
Solicitation # 75H71026Q00223
The Navajo Area Indian Health Service, Shiprock Service Unit, intends to award a sole-source, firm-fixed-price contract to Navajo Sanitation for solid waste collection services at the Dzilth-Na-O-Dith-Hle Health Center in Bloomfield, New Mexico, with performance beginning September 1, 2026, and ending August 31, 2027. The procurement is justified under unusual and compelling urgency due to the contractor’s unique, uninterrupted history of providing essential waste management services at the facility, ensuring continuity of operations critical to patient care. The North American Industry Classification System code is 562111, with a small business size standard of $47 million in annual revenue. No competitive solicitation will be issued unless a respondent submits clear and convincing evidence that competition would benefit the government. Responses must be submitted in writing as a capability statement by August 17, 2026, at 10:00 a.m. MST, and must not include proprietary, classified, confidential, or sensitive information. The government is not obligated to respond to or acknowledge submissions, and failure to receive affirmative responses will result in contract award without further notice. All information provided may be used in future solicitations if competition is pursued, and any resulting solicitation will be publicly announced on SAM.gov. The point of contact for inquiries is Ken Parrish, Purchasing Agent, reachable at ken.parrish@ihs.gov.
Department Of Health And Human Services

POSTED

7 days ago

DEADLINE

in 12 days
View Details
NAICS: 112990
Federal
NIDDK in vivo efficacy of Fc-bispecifics study
Solicitation # 75N98026Q00898TACONICBIOSCIENCESINC
The National Institute of Diabetes and Digestive and Kidney Diseases within the National Institutes of Health is seeking to advance its long-term research into novel antibody-protein conjugates designed to provide durable protection against HIV infection. This effort, funded by the Office of AIDS Research, focuses on evaluating the in vivo antiviral and immune-recruiting activity of a specific panel of conjugates known as APCs, which have previously demonstrated promising results in preventing HIV infection in cell-based and animal models. The current study will expand on a pilot investigation using humanized CD34+ mice, testing six groups of six mice each to assess five different APC formulations alongside a vehicle control. The research will measure viral load through PCR and flow cytometry of T-cells, with blood samples collected at designated timepoints leading to a terminal collection on day 56, followed by serum preparation and analytical processing to determine efficacy in both prophylactic and therapeutic settings. The work is based on earlier findings that highlighted the plasma stability and favorable pharmacokinetic profile of a glycosylated Fc-containing conjugate, mGRFT-Fc(glyc), which triggered strong immune and cytotoxic antiviral responses. This new phase aims to validate and build upon those results by conducting comprehensive in vivo efficacy assessments under controlled conditions at the Laboratory of Bioorganic Chemistry’s Natural Products Chemistry Section in Bethesda, Maryland. The solicitation, issued under the number 75N98026Q00898TACONICBIOSCIENCESINC, is a presolicitation notice with a response deadline in August 2026, and is open to entities capable of supporting complex preclinical research involving animal models, immunological assays, and advanced molecular diagnostics. The project is part of a broader, sustained initiative to develop next-generation biologics for HIV prevention and immune modulation, with all testing and analysis to be conducted in alignment with NIH’s intramural research mission and regulatory standards.
National Institutes Of Health Olao

POSTED

9 days ago

DEADLINE

in about 8 hours
View Details
NAICS: 541715
SBIR / STTR
NIH Small Business Technology Transfer Grant (Parent STTR [R41/R42] Clinical Trial Optional)
Solicitation # PA-27-102
This solicitation supports Small Business Technology Transfer (STTR) grants through the National Institutes of Health to fund research and development projects that advance innovative technologies with potential for commercialization, requiring a formal collaboration between a U.S.-owned small business and a nonprofit research institution. The award is made solely to the small business, regardless of where the principal investigator is employed, and projects must align with the missions of NIH, CDC, or FDA components. Funding is available for Phase I, Phase II, Direct to Phase II, and Fast-Track applications, with Fast-Track allowing combined Phase I and II review to streamline the process. Direct to Phase II is an option for businesses that have already demonstrated technical merit without prior Phase I funding, provided the application is submitted as a new proposal, not a renewal. Only one Phase II award is permitted per Phase I project, and Phase IIB Strategic Breakthrough applications must go through a separate solicitation. Applications must focus on feasibility or R&D that supports public health goals and are subject to restrictions on clinical trials, which are not permitted under this NOFO if exclusively aligned with specific NIH institutes including NIAID, NIAMS, NIDCR, NIDDK, NIMHD, NCATS, and ORIP. The funding opportunity is part of the broader SBIR/STTR mandate, which requires NIH to set aside 0.45% of its extramural budget for STTR, ensuring support for small businesses with fewer than 500 employees. Applicants are encouraged to consult with program staff prior to submission to ensure alignment with funding priorities and to use the Assignment Request Form to suggest an appropriate awarding component, though such identification is not mandatory. The solicitation closes on August 5, 2026, and information on program details, priorities, and frequently asked questions is available through the NIH Seed Fund portal and related government strategies including the Make Our Children Healthy Again initiative.
Department of Health and Human Services

POSTED

2 months ago

DEADLINE

in 8 months
View Details